WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals
World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

ISSN 2457-0400

Impact Factor  :  5.464

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • WJAHR New Impact Factor

    Its our Pleasure to Inform you that WJAHR Impact Factor has been increased from  4.897 to 5.464 due to high quality Publication at International Level

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR 1 January 2021 Issue has been Published, Kindly check it on http://www.wjahr.com/home/current_issues

  • WJAHR JANUARY ISSUE PUBLISHED

    JANUARY 2021 Issue has been successfully launched on 1 January 2021.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

EFFECT OF EMPAGLIFLOZIN ON HR VARIABILITY AND QT DISPERSION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS T2DM

Abdulaziz Jomaa Almohammad Alissa*, Houssam Balleh and Rouba Salman

ABSTRACT

Background: Individuals with type 2 Diabetes Mellitus(T2DM) are at high risk for development of cardiovascular complications. Treatment with empagliflozin may affect on impaired heart rate variability and impaired ventricular repolarization heterogeneity which associated with the risk of sudden cardiac death(SCD). Objective: the present study aims to assess the effects of empagliflozin on QT dispersion(QTd) and HR variability (HRV) in patients with T2DM. Materials and Methods This is prospective study conducted in the department of cardiology in Tishreen University Hospital-Lattakia -Syria from September 2019 to September 2020. Patients with T2DM who aged 42 to 80 with indication for treatment with empagliflozin were enrolled in the study. QT dispersion, HR variability were reordered before starting empagliflozin and the end of follow up. Results: A total of 40 patients were included, Median age was 52.5 years, 22 (55%) were male, hypertension was detected in 28(70%) of the patients. Empagliflozin reduced glycemia (186.10±54.9 vs125.72±33.3. p:0.0001), systolic blood pressure SBP(132.3±12.7vs 124.9±9.8, p:0.001),QTd (62.22±21.4 vs52.15±22.6, p:0.003), and increased SDNN(89.15±22.2 vs96.40±21.2,p:0.03) in the study participants. Spearman's correlation analysis revealed positive correlation between changes in SBP and QTd(Spearman's =0.6, P=0.0001) and negative correlation with SDNN(Spearman's =-0.3, P=0.02). Reduction in glycemia was correlated with increased in QTd(Spearman's = -0.2, P=0.07) and decreased in SDNN(Spearman's = 0.1, P=0.3). Conclusion: Empagliflozin alters ventricular repolarization indices and impaired HRV, and this could be the mechanism by which empagliflozin reduced cardiovascular events.

[Full Text Article]